Hjem › Epitelcellekarcinom i eggstokkene › Minnesota
Kliniske studier for Epitelcellekarcinom i eggstokkene i Minnesota
7 studier for Epitelcellekarcinom i eggstokkene søker deltakere på steder i Minnesota.
Byer i Minnesota
Offisiell studietekst (engelsk)
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of Minnesota - Minneapolis /ID# 275718, Minneapolis
- Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Masonic Cancer Center, University of Minnesota, Minneapolis
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 15. sep. 2026 · NCT06915025ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Mayo Clinic (Rochester), Rochester
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Minneapolis
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 21. jul. 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Minnesota Oncology Hematology PA, Minneapolis
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 2. jul. 2026 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. mar. 2026 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- SCRI - Minnesota Oncology Hematology, P.A., Minneapolis
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 23. des. 2025 · NCT06690775Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.